The company's main goal is to enhance and restore the immune system of patients with cancer, chronic viral or bacterial infections, or those undergoing lympho-depleting treatments such as chemotherapy or bone marrow transplantation. Cytheris is particularly interested in the development of a recombinant human interleukin-7 for immune reconstitution in immuno-depressed patients.